

**April 09, 2025**

National Stock Exchange of India Limited,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai-400051

BSE Limited  
Phiroze Jeejeebhoy Towers, Dalal  
Street, Fort, Mumbai-400001

Symbol: **ORCHPHARMA**

Scrip Code: **524372**

**Ref: (i) Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015 ('SEBI Listing Regulations')**

**(ii) SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024**

**Sub: Intimation under Regulation 30 of SEBI Listing Regulations in relation to the entering into a Joint Memo of Compromise with DBS Bank India Limited**

Dear Sir/Madam,

With reference to the captioned subject, this is to inform you that Company has entered into a Joint Memo of Compromise ('Memo') with DBS Bank India Limited ('DBS Bank') to conclude the prolonged dispute pending with Hon'ble National Company Law Tribunal, over the lease rentals of the property in possession of the Company located at Patibulum Village, Kancheepuram District, Tamil Nadu owned by DBS Bank.

The Company has entered into above Memo to settle, compromise and finally and forever resolve all disputes and claims that may exist with DBS Bank for the lease rentals from April 01, 2020 till December 31, 2024. Additionally, the Company has entered into a lease agreement for the aforesaid property thereby mitigating the risk henceforth.

Details of Memo and relevant terms & conditions as required under Regulation 30 read with Para B Sub-para- 5 of Part A of Schedule III of SEBI Listing Regulations and SEBI Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 are enclosed herewith as **Annexure-I**.

You are requested to take the above on record.

Thanking You,  
For **Orchid Pharma Limited**

**Kapil Dayya**  
**Company Secretary & Compliance Officer**

**Encl.: as above**

**Annexure-I**

**Regulation 30 read with Para B Sub-para- 5 of Part A of Schedule III of SEBI Listing Regulations and SEBI Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024**

<b>Particulars</b>	<b>Details of Joint Memo of Compromise</b>
Name(s) of parties with whom the agreement is entered	DBS Bank India Limited and Orchid Pharma Limited jointly with Dhanuka Laboratories Limited
Purpose of entering into the agreement	Settle, compromise and finally and forever resolve all disputes and claims that may exist with DBS Bank for the lease rentals from April 01, 2020 till December 31, 2024
Size of agreement	Rs.7.62 Crores
Shareholding, if any, in the entity with whom the agreement is executed	Nil
Significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc.;	The parties agree for successfully closing/disposal of the IA 700 at the Hon'ble National Company Law Tribunal and not to initiate any legal proceeding against the Company including but not limited to proceeding to claim interest, penalty or damage in relation to the claim of lease rental from April 01, 2020 to December 31, 2024.
Whether the said parties are related to promoter/promoter group/ group companies in any manner. If yes, nature of relationship	Not related
Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length	No
In case of issuance of shares to the parties, details of issue price, class of shares issued;	Not Applicable
In case of loan agreements, details of lender/borrower, nature of the loan, total amount of loan granted/taken, total amount outstanding, date of execution of the loan agreement/sanction letter, details of the security provided to the lenders / by the borrowers for such loan or in case outstanding loans lent to a party or borrowed from a party become material on a cumulative basis;	
Any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc.	
In case of termination or amendment of agreement, listed entity shall disclose additional details to the stock exchange(s): i. name of parties to the agreement; ii. nature of the agreement; iii. date of execution of the agreement; iv. details of amendment and impact thereof or reasons of termination and impact thereof.	